Form 8-K - Current report:
SEC Accession No. 0001628280-21-024814
Filing Date
2021-12-10
Accepted
2021-12-10 11:14:22
Documents
15
Period of Report
2021-12-10
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crdf-20211210.htm   iXBRL 8-K 38033
2 EX-99.1 a991ex121021.htm EX-99.1 14468
6 crdf-20211210_g1.jpg GRAPHIC 176318
7 image_0a.jpg GRAPHIC 17916
  Complete submission text file 0001628280-21-024814.txt   650096

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT crdf-20211210.xsd EX-101.SCH 1935
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT crdf-20211210_lab.xml EX-101.LAB 23007
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT crdf-20211210_pre.xml EX-101.PRE 12131
8 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20211210_htm.xml XML 10069
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35558 | Film No.: 211484305
SIC: 2836 Biological Products, (No Diagnostic Substances)